Cancer
Malignant Thyroid Gland Neoplasm
CI-CAN-00003251Explore in graph →
Top-level176 active trials10 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003251Explore in graph →
Clinical trials
790 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (65)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT07777536 | Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer | recruiting | Phase 2 | 72 | Fudan UniversityOTHER | 1 | Aug 20, 2026 |
| clinicaltrials |
| NCT06931743 | The Application of Electrical Stimulation in Postoperative Pain Management of Thyroid Surgery | recruiting | N/A | 668 | Xiaonan HuangOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05025046 | NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules | completed | — | 250 | Rigen BiotechINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05453799 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer | suspended | Phase 2 | 54 | Northwestern UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07752277 | Quantitative Pharmacology-Based Dose Adjustment Protocol in Postoperative Thyroid Cancer Patients | completed | — | 124 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT00936858 | RAD001 for Patients With Radioiodine Refractory Thyroid Cancer | completed | Phase 2 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT02657551 | A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07496684 | Application and Evaluation of Vision-LSTM Modeling in Diagnostic Ultrasound Imaging of TI-RADS Category 4b Thyroid Nodules | completed | — | 401 | Ma ZheOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03215095 | RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers | active not recruiting | Early Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04675710 | Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05591092 | Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery | terminated | — | 2 | Mayo ClinicOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07059507 | Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy.(GD) | recruiting | — | 280 | Minia UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07652450 | Incidental Thyroid Cancer in Cases With Inflammatory Thyroid Lesion(Thyroid cancer) | completed | N/A | 98 | Minia UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04171622 | Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | active not recruiting | Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04623801 | Laser Ablation of Papillary Thyroid Microcarcinoma | active not recruiting | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06738888 | Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy | recruiting | — | 300 | Shanghai 6th People's HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07255482 | Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial | completed | — | 874 | Brigham and Women's HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 4 | 12 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07755423 | Stereotactic Body Radiotherapy for the Treatment of Distant Metastases in Thyroid Cancer: A Phase II Prospective Clinical Study | enrolling by invitation | — | 44 | Fudan UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04280081 | A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation(LIBRETTO-321) | active not recruiting | Phase 2 | 77 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06498674 | AI-Assisted Ultrasound Review Before Thyroid Surgery | completed | N/A | 515 | Fujian Medical UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07753499 | Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer | recruiting | N/A | 120 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT01412762 | Measuring Patient Expectations for Thyroid Surgery | active not recruiting | — | 138 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07713901 | Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma | enrolling by invitation | — | 93,600,000 | Novo Nordisk A/SINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07225309 | A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer | recruiting | N/A | 300 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Aug 3, 2026 | clinicaltrials |
| NCT03099356 | Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer | recruiting | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03914300 | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | active not recruiting | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07259304 | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | active not recruiting | — | 118 | University of Southern CaliforniaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07470489 | Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer | not yet recruiting | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT01833650 | The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer | completed | N/A | 120 | Cyprus University of TechnologyOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03181100 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06411834 | Mapping Patient Decision-making in Thyroid Cancer | not yet recruiting | N/A | 50 | University of California, Los AngelesOTHER | 0 | Jul 24, 2026 | clinicaltrials |
| NCT06458036 | Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)(RAISE) | recruiting | Phase 2 | 13 | Children's Hospital of PhiladelphiaOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04877613 | GFRα4 CAR T Cells in MTC Patients | active not recruiting | Phase 1 | 9 | University of PennsylvaniaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT01141309 | Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer | active not recruiting | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07234539 | Evaluation of an Artificial Intelligence-enabled Clinical Assistant to Support Thyroid Cancer Management | enrolling by invitation | N/A | 76 | The University of Hong KongOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03892993 | Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers | recruiting | N/A | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT07521670 | Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)(STRAP) | not yet recruiting | Phase 2 | 68 | National Cancer Centre, SingaporeOTHER | 4 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07302672 | Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma | recruiting | N/A | 108 | Ming-an YuOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07695974 | Clinicopathological Predictors of Recurrence in Papillary Thyroid Carcinoma | completed | — | 1,113 | University of Roma La SapienzaOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06958601 | Safety and Efficacy of Transoral Robotic Thyroidectomy Versus Traditional Open Thyroidectomy for Thyroid Cancer | completed | — | 430 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07545837 | Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors | recruiting | N/A | 20 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03085056 | Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | active not recruiting | Early Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03345563 | Project HERO: Health Empowerment & Recovery Outcomes(HERO) | completed | N/A | 113 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04238624 | Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | active not recruiting | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 25 | Kaiser PermanenteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 25, 2026source: clinicaltrials